This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Clinical Information​Stroke Prevention in Atrial Fibrillation​Morbidity and Mortality​Efficacy​Aristophanes​Safety​Real-world Data​Guideline recommendations​Persistence and Adherence​Dosing​Summary​Venous Thromboembolism TreatmentEfficacySafety​Real-world Data​Guideline recommendationsDosing​Venous Thromboembolism PreventionEfficacy​Safety​Dosing​Eliquis Important Safety InformationEliquis Abbreviated Prescribing Information (2.5 mg)​Eliquis Abbreviated Prescribing Information (5 mg) Support & Services​ Support & Services​ Self-detail presentations​ Webinars​ MaterialsVideos​
Overview of Real-World Data​Real-world settings study demonstrated a significantly higher risk of hospitalization (all-cause, stroke/SE, and major bleeding) associated with warfarin, a significantly higher risk of major bleeding hospitalization associated with dabigatran or rivaroxaban, and a significantly higher risk of all-cause hospitalization associated with rivaroxaban compared to apixaban. Lower major bleeding-related costs were observed for apixaban patients compared to warfarin and rivaroxaban patients.3Eliquis® was associated with a lower risk of major bleeding (hazard ratio = 0.44 [95% CI: 0.12–0.97]) compared with VKA.4
Evidence of the safety of NOAC use in the real-world setting and may facilitate clinical decision making, especially in Italy where data on the real-world use of NOACs have been lacking.4​
*Study lives indicate the number of patient records examined; while known duplicate records have been removed, these may not represent discrete patient lives. Numbers are accurate as of January 2020.​

†Based on transferability of trial findings to clinical practice​

NOAC: non-vitamin K antagonist oral anticoagulant; US: United States
References:  1. ELIQUIS ® 2.5 mg/ 5 mg Egyptian Drug Authority approved leaflet 17/08/2022. Revision Date: February 2022. 2. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8:699-708. 3. Amin A, Keshishian A, Vo L, et al. Real-world comparison of all- cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. J Med Econ. 2018;21(3:244-253. 4. Ramagopalan S, Allan V, Saragoni S, et al. Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. J Comp Eff Res. 2018;7(11:1063-1071. 5. Lip GYH, Keshishian A, Li X, et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018;49(12:2933-2944. 6. Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 2017;33(11:1955-1963. 7. Amin A, Keshishian A, Trocio J, et al. Risk of stroke/ systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595- 1604. 8. Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients. J Am Heart Assoc. 2017;6(2). pii:e004517. 9. Lip GY, Pan X, Kamble S, et al. Major bleeding risk among nonvalvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70(9):752-763. 10. Xie L, Vo L, Keshishian A, et al. Comparison of hospital length of stay and hospitalization costs among patients with nonvalvular atrial fibrillation treated with apixaban or warfarin: An early view. J Med Econ. 2016;19(8):769-776. 11. Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost. 2018;118(3):526-538.​ Explore more​VTE treatment Dosing​ Learn more Loading
Click here for Eliquis® 2.5mg Prescribing Information

Click here for Eliquis® 5mg Prescribing Information
Invalidation Date : 21/08/2024​
Quick Links
SPAF Guideline recommendations​
Learn moreLoading
SPAF Aristophanes​
Learn more Loading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.